PolyTherics Ltd, a UK-based company applying precision chemistry to the development of improved protein and peptide-based drugs, has announced the departure of its CEO and board member Keith Powell. Dr Powell is leaving to pursue other interests. He will be replaced as CEO by the current chief business officer, John Burt. Dr Burt, who was previously the CEO of Thiakis, will also join the board of PolyTherics.
Copyright 2011 Evernow Publishing Ltd